Court blocks temporary stop on export production of semaglutide
The Delhi High Court has denied a request to immediately stop an Indian drugmaker from producing semaglutide for export. The decision clears the way for continued manufacturing while the legal fight continues, with the matter set for further review in January.
What the ruling means
Semaglutide is a widely used medicine for diabetes and weight management. A global patent holder sought an interim injunction to prevent an Indian firm from making the drug for export, arguing patent rights were being infringed. The court refused that request, allowing production to continue for now.
Why January matters
The case will be revisited by the court in January. That hearing could determine longer-term restrictions or confirm that production can proceed. For now, manufacturers can continue exporting semaglutide while preparations for the next procedural steps move forward.
Market implications for Indian drugmakers
- Competitive pressure ahead: The patent for semaglutide is set to expire in 2026. Indian companies are ramping up capacity to enter a large and growing market for GLP-1 medicines.
- Export focus: Keeping production active for export helps companies secure international contracts and scale manufacturing before patent expiry.
- Price and access: More suppliers typically mean lower prices and wider availability, which could expand access to treatment globally.
- Ongoing legal risk: The pending court review means outcomes are still uncertain. Manufacturers and buyers remain watchful for any change after the January hearing.
What to watch next
Stakeholders will be watching the January court date closely. A final decision could influence timing for generic launches, pricing strategies, and international supply deals. For now, the ruling maintains the status quo and keeps export lines open while the legal process continues.